Source: Eur Respir J 2015; 45: 463-472
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Tagami Takashi, Matsui Hiroki, Horiguchi Hiromasa, Fushimi Kiyohide, Yasunaga Hideo. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J 2015; 45: 463-472

Member's Comments

No comment yet.

Related content which might interest you: Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Is COPD pharmacotherapy associated with increased incidence of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008 Hospital-acquired pneumonia in patients receiving immunosuppressive therapy Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019 Year: 2019 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019 Year: 2019